

Welcome to STN International! Enter x:x

LOGINID: sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 AUG 15 Indexing from 1937 to 1946 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 30 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31 AUG 15 PATDPAFULL: one FREE connect hour, per account, in
September 2003
NEWS 32 AUG 15 PCTGEN: one FREE connect hour, per account, in
September 2003
NEWS 33 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in
September 2003
NEWS 34 AUG 15 TEMA: one FREE connect hour, per account, in
September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

NEWS HOURS MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
NEWS INTER AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS LOGIN STN Operating Hours Plus Help Desk Availability
NEWS PHONE General Internet Information
NEWS WWW Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:32:03 ON 18 AUG 2003

FILE 'REGISTRY' ENTERED AT 12:38:11 ON 18 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3
DICTIONARY FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See **HELP CROSSOVER** for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10050376.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 12:38:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16548 TO ITERATE

6.0% PROCESSED      1000 ITERATIONS          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      323266 TO 338654
PROJECTED ANSWERS:          0 TO      0
```

L2 0 SEA SSS SAM L1

```
=> s 11 full
FULL SEARCH INITIATED 12:38:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 328733 TO ITERATE
```

```
100.0% PROCESSED 328733 ITERATIONS          177 ANSWERS
SEARCH TIME: 00.00.26
```

L3 177 SEA SSS FUL L1

```
=> fil caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          148.15        150.25
```

FILE 'CAPLUS' ENTERED AT 12:39:02 ON 18 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Aug 2003 VOL 139 ISS 8

FILE LAST UPDATED: 17 Aug 2003 (20030817/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 23 L3

=> d ibib abs hitstr 1-23

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2003:376819 CAPLUS
 DOCUMENT NUMBER: 138:385173
 TITLE: Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease
 INVENTOR(S): Diane, John; Meillasson, Michael; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; King, Larry; Seal, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy; Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SOURCE: PCT Int. Appl., 1243 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200304096	A2	20030515	WO 2002-US36072	20021108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, HK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		
WO 200304096	A2	20030515	WO 2002-XA36072	20021108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, HK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		

PRIORITY APPN. INFO.: US 2001-337122P P 20011108
 US 2001-344086P P 20011228
 US 2002-345635P P 20021013
 WO 2002-US36072 A 20021108

OTHER SOURCE(S): MARPAT 138:385173
 GI


L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

Absolute stereochemistry.



RN 388066-92-0 CAPLUS
 CN 2-Pyrrolidinonecarboxamide, 1-[3-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 388067-16-1 CAPLUS
 CN 2-Pyrrolidinonecarboxamide, 1-[3-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



AB The title compds. (I: R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO2, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxalkyl, etc.; R5 = R6X (wherein X = CO, SO2, (un)substituted CH2; R6 = (un)substituted Ph, naphthyl, indanyl, etc.); R25 = H, alkyl, alkoxy, etc.) which have activity as inhibitors of β -secretase and are therefore useful in treating a variety of disorders, such as Alzheimer's disease. The prep. (e.g., a multi-step synthesis of (1S,2R)-I, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid, was given. The compds. I showed IC50 of < 20 μ M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.


IT 388066-79-3 CAPLUS
 527714-28-9 527714-81-4P 527714-85-8P
 527716-76-3P 527717-66-4P 527726-64-3P
 527727-13-5P 527727-30-6P 527728-42-3P
 527728-43-4P 527728-70-7P 527728-83-2P
 527728-97-8P 527728-98-9P 527729-08-4P
 527729-09-5P 527729-12-0P 527730-27-4P
 527732-52-1P 528116-70-3P

RN 388066-79-3 CAPLUS
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BTOI (Biological study); PREP (Preparation); USES (Uses)


(prop., of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease)

RN 388066-79-3 CAPLUS
 CN 2-Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-iodophenyl)methyl]amino]propyl]-4-hydroxy-3-[(1-pyrrolidinylcarbonyl)-(SC1) (CA INDEX NAME)

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 527714-28-9 CAPLUS
 CN Acetic acid, 2-ethyl-1-(2-hydroxy-3-[(3-hydroxy-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-4-phenylbutyl)hydrazide (9CI) (CA INDEX NAME)




RN 527714-81-4 CAPLUS
 CN Benzoic acid, 3-ethyl-, 2-ethyl-2-[2-hydroxy-3-[(3-hydroxy-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-4-phenylbutyl]hydrazide (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 527714-85-8 CAPLUS
 CN Pentanoic acid, 4-methyl-, 2-ethyl-2-[2-hydroxy-3-[(3-hydroxy-4-(1-pyrrolidinylcarbonyl)benzyl)amino]-4-phenylbutyl]hydrazide (SCI) (CA INDEX NAME)




RN 527716-76-3 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527717-66-4 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527726-64-3 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[(2-propyl-1-pyrrolidinyl)carbonyl]-, monohydrochloride (SCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl
 RN 527727-13-5 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527727-30-6 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-(2-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527728-42-3 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-(1-methylethyl)phenyl)methyl]amino]propyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527728-43-4 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 527728-70-7 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(ethylmethoxyamino)sulfonyl]-5-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527728-98-9 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1-(3-ethynylphenyl)cyclopropyl)amino]-2-hydroxypropyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 527728-97-8
 CMF C36 H39 F2 N3 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 527729-08-4 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(1,1-dimethylethyl)amino]sulfonyl]-5-[(2S)-2-(methoxymethyl)-1-



RN 527728-83-2 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]sulfonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527728-97-8 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1-(3-ethynylphenyl)cyclopropyl)amino]-2-hydroxypropyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 527729-09-5 CAPLUS
 CN Benzamide, 3-[(2S)-2-butyl-1-pyrrolidinyl]carbonyl]-N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527729-12-0 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[(2R)-2-(propoxymethyl)-1-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527730-27-4 CAPLUS


CN Formic acid, compd. with N-[(1s,2s)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[(2s)-2-propyl-1-pyrrolidinyl]carbonyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 527730-26-3

CMF C35 H43 F2 N3 O3

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 527732-52-1 CAPLUS

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Benzamide, N-[(1s,2s)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(2s)-2-ethyl-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528116-70-3 CAPLUS

CN Benzamide, N-[(1s,2s)-1-[(3,5-difluorophenyl)methyl]-3-[(1-(3-ethylphenyl)cyclopropyl)amino]-2-hydroxypropyl]-3-[(2s)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:794312 CAPLUS

DOCUMENT NUMBER: 137:310704

TITLE: Preparation of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics

INVENTOR(S): Gremmels, Uwe Joerg; Priepke, Henning; Nar, Herbert; Stassen, Jean-Marie; Wienen, Wolfgang

PATENT ASSIGNEE(S): Guerbet, S.A.

SOURCE: U.S. Pat. Appl. Publ., 31 pp.

CODEN: USXKCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002151534	A1	20021017	US 2002-50376	20020116
DE 10104597	A1	20020808	DE 2001-10104597	200110202
DE 10136435	A1	20030213	DE 2001-10136435	20010726


PRIORITY APPLN. INFO.: DE 2001-10104597 A 20010202

US 2001-268569P 20010202

DE 2001-10136435 A 20010726

OTHER SOURCE(S): MARPAT 137:310704

GI



AB The title compds., (e.g., (I)), wherein m = 0, 1, 2; n = 0, 1; A = (C1-C3)alkylene, a bond, etc.; R1 = amino, (C1-C5)alkylamino, (C3-C7)cycloalkylamino, phenyl (C1-C3)alkylamino, etc.; R2 = H, F, Cl, Br, etc.; R3 = H, (C1-C3)alkyl; R4 = H, (C1-C3)alkyl; Ar = substituted Ph, naphthyl) were prepnd. Thus, N-(5-carbamimidoyl-2-hydroxybenzyl)-3-chloro-4-(pyrrolidin-1-ylcarbonyl)benzamide hydrochloride was prepnd. by a multistep synthesis. The prepnd. compds. are useful as antithrombotic agents. Data for biol. activity of title compds. were given.

IT 445256-53-1 446025-38-3

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics)

RN 445256-53-1 CAPLUS


CN Benzenoacetic acid, 3-(aminoiminomethyl)-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 445256-32-6

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CMF C24 H28 N4 O4

PAGE 1-A

CM 2
CRN 64-19-7
CMF C2 H4 O2RN 446025-38-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 2-A



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A



● HCl

IT 445256-14-4P 445256-20-2P 445256-36-0P
 445256-21-3P 445256-41-7P 445256-42-8P
 445256-47-3P 445256-50-5P 446025-31-6P
 446025-37-4P 446025-48-0P 446025-41-8P
 446025-43-0P 446025-44-1P 446025-45-2P
 446025-46-3P 446025-47-4P 446025-48-5P
 446025-50-9P 446025-51-0P 446025-52-1P
 446025-53-2P 446025-54-3P 446025-55-4P
 446025-56-5P 446025-57-6P 446025-58-7P
 446025-59-8P 446025-60-1P 446025-61-2P
 446025-62-3P 446025-63-4P 446025-64-5P
 446025-65-6P 446025-66-7P 446025-67-8P
 446025-68-9P 446025-69-0P 446025-70-3P
 446025-71-4P 446025-72-5P 446025-73-6P
 446025-77-0P 446025-78-1P 446025-88-3P

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

446025-90-7P 446025-91-8P 446025-93-0P

446025-95-2P 446025-96-3P 446025-97-4P

446025-98-5P 446025-99-6P 446026-00-2P

446026-02-4P 446026-03-5P 446026-04-6P

446026-05-7P 446026-06-8P 446026-07-9P

446026-08-0P 446026-09-1P 446026-10-4P

446026-11-5P 446026-12-6P 446026-13-7P

446026-14-8P 446026-15-9P 446026-16-0P

446026-17-1P 446026-18-2P 446026-19-3P

446026-20-6P 471868-50-5P 471869-06-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidophenylacetamides and analogs as anti-thrombotics)

RN 445256-14-4 CAPLUS

CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A



● HCl


RN 445256-20-2 CAPLUS
 CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 445256-36-0 CAPLUS
 CN Benzenoacetic acid, 3-(aminoiminomethyl)-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



PAGE 1-A



● HCl

RN 445256-38-2 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A

RN 445256-41-7 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 445256-41-7 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A

RN 445256-47-3 CAPLUS
 CN Benzenoacetic acid, 3-(aminoiminomethyl)-,alpha.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino)- (9CI) (CA INDEX NAME)

RN 446025-30-5 CAPLUS
 CN Benzamide, N-[(3-(aminoiminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A



PAGE 2-A



● HCl



RN 446025-31-6 CAPLUS

CN Benzanide, N-[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-37-2 CAPLUS

CN Benzanide, N-[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl



RN 446025-39-4 CAPLUS

CN Benzenespropanoic acid, 3-(aminoiminomethyl)-.beta.-{[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-41-8 CAPLUS

CN Benzenespropanoic acid, 3-(aminoiminomethyl)-.beta.-{[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 446025-43-0 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446025-44-1 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A



● HCl

RN 446025-45-2 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 446025-46-3 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

PAGE 2-A



PAGE 2-A



● HCl

● HCl

RN 446025-47-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-48-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-chloro-4-(1-pyrrolidinylcarbonyl)benzyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

PAGE 2-A



PAGE 2-A



● HCl

● HCl

RN 446025-50-9 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-51-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl



RN 446025-52-1 CAPLUS
 CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446025-53-2 CAPLUS
 CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





● HCl

RN 446025-54-3 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-{[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446025-55-4 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-{[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, monohydrochloride (9CI) (CA INDEX NAME)




RN 446025-57-6 CAPLUS
 CN Benzamide, 3-[(3-(aminomethyl)phenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-56-5 CAPLUS
 CN Benzamide, N-[(3-(aminomethyl)phenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




● HCl

RN 446025-58-7 CAPLUS
 CN Benzenesacetamide, 3-(aminomethyl)-N-ethyl-, alpha, -[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl





● HCl

RN 446025-60-1 CAPLUS
 CN Glycine, 3-[(3-(aminomethyl)phenyl)-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-beta,-alanyl-N-propyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)





RN 446025-61-2 CAPLUS
 CN Benzamide, N-[1-(5-(aminomethyl)-2-hydroxyphenyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-62-3 CAPLUS
 CN Benzamide, N-[1-(5-(aminomethyl)-2-hydroxyphenyl)ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



RN 446025-63-4 CAPLUS
 CN Benzamide, N-[1-(5-(aminomethyl)-2-hydroxyphenyl)ethyl]-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 446025-64-5 CAPLUS
 CN Benzenepropionic acid, 3-(aminomethyl)-.beta.-{[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino}-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

● HCl

PAGE 1-A



PAGE 2-A





L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 446025-65-6 CAPLUS
CN Benzanide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 446025-66-7 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 446025-67-8 CAPLUS
CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-68-9 CAPLUS
CN Benzenepropanoic acid, 3-[(hexyloxy)carbonyl]amino]iminomethyl]-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





RN 446025-69-0 CAPLUS
CN Benzenepropanoic acid, 3-((benzoylamino)iminomethyl)-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, propyl ester (9CI) (CA INDEX NAME)



● HCl





RN 446025-70-3 CAPLUS
CN Benzenepropanoic acid, 3-[(imino{[(2,2,2-trichloroethoxy)carbonyl]amino}methyl)-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 446025-71-4 CAPLUS
CN Carbamic acid, [(4-hydroxy-3-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]methyl)phenyl]iminomethyl-, hexyl ester (9CI) (CA INDEX NAME)





RN 446025-72-5 CAPLUS
CN Benzamide, N-[(5-[(benzoylamino)iminomethyl]-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 446025-73-6 CAPLUS
 CN Benzamide, N-[(2-hydroxyamino)iminomethyl]phenylmethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 446025-77-0 CAPLUS
 CN Benzamide, N-[(3-(aminoiminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 446025-78-1 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

RN 446025-88-3 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446025-90-7 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-91-8 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446025-93-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-95-2 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A

RN 446025-96-3 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-97-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A

RN 446025-98-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446025-99-6 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446026-00-2 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-02-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446026-03-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.-[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-04-6 CAPLUS
 CN Glycine, 3-[3-(aminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446026-05-7 CAPLUS
 CN Glycine, 3-[3-(aminiminomethyl)phenyl]-N-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)-.beta.-alanyl-N-propyl- (9CI) (CA INDEX NAME)

RN 446026-06-8 CAPLUS
 CN Benzenepropanoic acid, 3-(aminiminomethyl)-.beta.-[(3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




PAGE 2-A




RN 446026-07-9 CAPLUS
 CN Benzenepropanamide, 3-(aminiminomethyl)-N,N-dimethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-08-0 CAPLUS
 CN Benzamide, N-[1-(3-(aminiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 446026-09-1 CAPLUS
 CN Benzeneacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A

RN 446026-10-4 CAPLUS
 CN Benzeneacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino- (9CI) (CA INDEX NAME)





PAGE 1-A



PAGE 2-A

RN 446026-11-5 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A





PAGE 2-A

RN 446026-12-6 CAPLUS
 CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, ethyl ester (9CI) (CA INDEX NAME)

RN 446026-13-7 CAPLUS
 CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446026-14-8 CAPLUS
 CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 446026-15-9 CAPLUS
 CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-A



RN 446026-16-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-{[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino}-, ethyl ester (9CI) (CA INDEX NAME)



RN 446026-17-1 CAPLUS
 CN Benzamide, N-[(1-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446026-18-2 CAPLUS
 CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[(3-methyl-4-(1-pyrrolidinyl)carbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

RN 446026-19-3 CAPLUS
 CN Benzenepropanoic acid, 3-[[[hexyloxy]carbonyl]amino]iminomethyl-.beta.-[(3-methyl-4-(1-pyrrolidinyl)carbonyl)benzoyl]amino-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 1-A


PAGE 2-A




PAGE 2-A

RN 446026-20-6 CAPLUS
 CN Benzamide, N-[(2-hydroxy-5-[(hydroxylamino)iminomethyl]phenyl)methyl]-3-methyl-4-(1-pyrrolidinyl)carbonyl- (9CI) (CA INDEX NAME)

RN 471868-50-5 CAPLUS
 CN Carbonic acid, 4-[(benzoylamino)iminomethyl]-2-[[3-methyl-4-(1-pyrrolidinyl)carbonyl)benzoyl]amino]methylphenyl ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A



IT 471869-69-9


RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and
analog as antithrombotics)
RN 471869-69-9 CAPLUS
Benzamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



PAGE 2-A

RN 471869-06-4 CAPLUS

CN Benzenepropanamide, 3-(aminomethyl)-N-ethyl-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzyl)amino- (9CI) (CA INDEX NAME)



IT 445256-18-8P 445256-19-9P 446026-21-7P
446026-26-2P 446026-27-3P 446026-28-4P

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN


(Continued)

446026-30-8P 446026-35-3P 446026-37-5P

446026-39-7P 446026-40-0P 446026-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and
analog as antithrombotics)

RN 445256-18-8 CAPLUS

CN Benzamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

PAGE 1-A



RN 445256-19-9 CAPLUS

CN Benzamide, N-[(5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A

IT 446026-21-7 CAPLUS


CN Benzoic acid, 3-cyano-.alpha.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)




RN 446026-26-2 CAPLUS
 CN Benzamide, 3-chloro-N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 446026-27-3 CAPLUS
 CN Benzenepropanoic acid, 3-cyano-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-28-4 CAPLUS
 CN Benzenepropanamide, 3-cyano-N,N-dimethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)




RN 446026-30-8 CAPLUS
 CN Benzenamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-35-3 CAPLUS
 CN Benzenepropanoic acid, 3-cyano-.beta.-[(4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 446026-37-5 CAPLUS
 CN Benzamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-39-7 CAPLUS
 CN Benzenepropanoic acid, 5-cyano-2-hydroxy-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)



RN 446026-40-0 CAPLUS
 CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-A



PAGE 2-A



PAGE 2-A

• HCM


RN 446026-42-2 CAPLUS
CN Benzamide, N-[5-[(hydroxymethyl)iminomethyl]-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI)
(CA INDEX NAME)

14 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:615593 CAPLUS
DOCUMENT NUMBER: 137:169323
TITLE: Preparation of benzimidomethylbenzamidines and analogs
as factor Xa inhibitors
INVENTOR(S): Ries, Uwe; Joerg, Prieplke, Henning; Nar, Herbert;
Stassen, Jean-Marie; Steenen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 108 pp.
CODEN: FIXX2D
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062778	A2	20020815	WO 2002-EP823	20021026
W:	IE, AG, IL, AM, NT, AU, CZ, BE, BR, BG, CR, RU, DK, DM, DE, ES, FR, ES, FI, GR, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW	AM, AZ, BY, BG, CR, CZ, DK, DM, DE, ES, FR, ES, FI, GR, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW	AM, AZ, BY, BG, CR, CZ, DK, DM, DE, ES, FR, ES, FI, GR, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW	AM, AZ, BY, BG, CR, CZ, DK, DM, DE, ES, FR, ES, FI, GR, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW
RW:	GH, GM, KE, LS, MW, MD, SD, SI, SZ, TZ, UG, 2M, ZW, AT, CY, DE, DK, ES, FI, FR, GR, IR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, GM, GA, GN, GO, GW, ML, MR, NE, SN, TD	GH, GM, KE, LS, MW, MD, SD, SI, SZ, TZ, UG, 2M, ZW, AT, CY, DE, DK, ES, FI, FR, GR, IR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, GM, GA, GN, GO, GW, ML, MR, NE, SN, TD	GH, GM, KE, LS, MW, MD, SD, SI, SZ, TZ, UG, 2M, ZW, AT, CY, DE, DK, ES, FI, FR, GR, IR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, GM, GA, GN, GO, GW, ML, MR, NE, SN, TD	GH, GM, KE, LS, MW, MD, SD, SI, SZ, TZ, UG, 2M, ZW, AT, CY, DE, DK, ES, FI, FR, GR, IR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, GM, GA, GN, GO, GW, ML, MR, NE, SN, TD
DE 10104597	A1	20020808	DE 2001-10104597	20010202
PRIORITY APPLN. INFO.:			DE 2001-10104597 A	20010202
OTHER SOURCE(S):	MARPAT 137:169323		DE 2001-10135435 A	20010726

DE
OTHER SOURCE(S): MARPAT 137:169323

GI




AB Title compds., e.g., R1Z1Z2Z3NHZn [I; R = Z4R4; R1 = cycloalkylamino, cycloalkylaminocarbonyl, 2,5-dihydroxypropylcarboxyl, etc.; R2 = (alkoxycarbonyl)amidino, C:(NH)HOOCCH2CF3, or C:(NH)NH2 and Z4 = 2-hydroxy- or 2-alkoxycarbonyl-1,5-phenylene or R4 = (di)alkylamino, alkoxycarbonylamidino, or C:(NH)NH2 and Z4 = (2-hydroxy)-1,3-phenylene; Z = (un)substituted CH2; Z1 = (un)substituted 1,4-phenylene; Z2 = bond or bond/CO] were prep'd. Thus, 4-pyrrolidinocarbonyl-3-methylbenzoic acid was amidated by 3-aminoethyl-4-benzyloxobenzonitrile (prep'n. each given to give, in 3 addnl. steps, title compd. II. Data for

biol. activity of I were given.
IT 445256-14-4P 445256-20-2P 445256-32-6P
445256-36-0P 445256-38-2P 445256-41-7P
445256-42-8P 445256-47-3P 446025-30-5P
446025-31-6P 446025-32-7P 446025-33-8P
446025-37-2P 446025-38-3P 446025-39-4P
446025-41-8P 446025-43-0P 446025-44-1P

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 446025-45-2P 446025-46-3P 446025-47-4P
 446025-48-5P 446025-50-9P 446025-51-0P
 446025-52-1P 446025-53-2P 446025-54-3P
 446025-55-4P 446025-56-5P 446025-57-6P
 446025-58-7P 446025-59-8P 446025-60-9P
 446025-61-2P 446025-62-3P 446025-63-4P
 446025-64-5P 446025-65-6P 446025-66-7P
 446025-67-8P 446025-68-9P 446025-69-0P
 446025-70-3P 446025-71-4P 446025-72-5P
 446025-73-6P 446025-74-7P 446025-77-0P
 446025-78-1P 446025-79-2P 446025-88-3P
 446025-90-7P 446025-91-8P 446025-93-0P
 446025-95-2P 446025-96-3P 446025-97-4P
 446025-98-5P 446025-99-6P 446026-00-2P
 446026-02-4P 446026-03-5P 446026-04-6P
 446026-05-7P 446026-06-8P 446026-07-9P
 446026-08-0P 446026-09-1P 446026-10-4P
 446026-15-5P 446026-12-6P 446026-13-7P
 446026-14-8P 446026-15-9P 446026-16-0P
 446026-17-1P 446026-18-2P 446026-19-3P
 446026-20-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
 (prop., of benzamidomethylbenzamidines and analogs as factor Xa inhibitor)



RN 44526-14-4 CPLUS
 CN Benzamide, N-[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrate (90%) (CP, INDEX, NAME)



PAGE 1-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 2-A

● HCl



RN 445256-20-2 CAPLUS
CN Benzamide, N-[(S-(aminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)RN 445256-32-6 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino-, ethyl ester (9CI) (CA INDEX NAME)L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A

PAGE 1-A

RN 445256-36-0 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 1-A

PAGE 2-A





● HCl

RN 445256-38-2 CAPLUS
CN Benzamide, N-[(5-(aminomiminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)RN 445256-41-7 CAPLUS
CN Benzamide, N-[(5-(aminomiminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

● HCl

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 445256-42-8 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinyl)carbonyl - (9CI) (CA INDEX NAME)

RN 445256-47-3 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-,alpha,-[{3-methyl-4-(1-pyrrolidinyl)carbonyl}benzoyl]amino- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-A




RN 446025-30-5 CAPLUS
 CN Benzamide, N-[(3-(aminoiminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinyl)carbonyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-31-6 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinyl)carbonyl-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

PAGE 1-A




● HCl

RN 446025-32-7 CAPLUS
 CN Benzenacetamide, 3-(aminomethyl)-N-ethyl-.alpha.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 2-A



● HCl




RN 446025-33-8 CAPLUS
 CN Benzenepropanamide, 3-(aminomethyl)-N-ethyl-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446025-37-2 CAPLUS
 CN Benzamide, N-((5-(aminiminomethyl)-2-hydroxyphenyl)methyl)-3-chloro-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● HCl

RN 446025-38-3 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A



PAGE 2-A



● HCl

PAGE 1-A



RN 446025-39-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-(3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 446025-41-8 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



PAGE 2-A



● HCl

RN 446025-43-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





● HCl

RN 446025-44-1 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)





● HCl

RN 446025-45-2 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



RN 446025-46-3 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinyl)carbonyl)benzyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)


RN 446025-47-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(4-(1-pyrrolidinyl)carbonyl)-3-(trifluoromethyl)benzoyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)




RN 446025-48-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-chloro-4-(1-pyrrolidinyl)carbonyl)benzoyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-50-9 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinyl)carbonyl)benzoyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A



PAGE 2-A



● HCl

RN 446025-51-0 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-{[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A




● HCl


RN 446025-52-1 CAPLUS

CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-.alpha.-alanyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A



PAGE 2-A



● HCl

RN 446025-53-2 CAPLUS

CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-.alpha.-alanyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A




● HCl


RN 446025-54-3 CAPLUS

CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-{[3-ethoxy-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A



PAGE 2-A



● HCl


RN 446025-55-4 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A




● HCl

RN 446025-56-5 CAPLUS
 CN Benzamide, N-[1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 446025-57-6 CAPLUS
 CN Benzenacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 446025-58-7 CAPLUS
 CN Benzenacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 446025-59-8 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
(NAME)


(Continued)



PAGE 1-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
(NAME)

(Continued)



PAGE 1-A



PAGE 2-A




PAGE 2-A

● HCl

RN 446025-60-1 CAPLUS
CN Glycine, 3-[3-(aminomiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzyl]-beta-alanyl-N-propyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)RN 446025-61-2 CAPLUS
CN Benzamide, N-[1-[5-(aminomiminomethyl)-2-hydroxymethyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
(NAME)


(Continued)



PAGE 1-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
(NAME)

(Continued)



PAGE 1-A



PAGE 2-A





PAGE 2-A

● HCl

RN 446025-62-3 CAPLUS
CN Benzamide, N-[1-[5-(aminomiminomethyl)-2-hydroxymethyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)RN 446025-63-4 CAPLUS
CN Benzamide, N-[1-[5-(aminomiminomethyl)-2-hydroxymethyl]ethyl]-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 446025-64-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminomethyl)-.beta.,-[{4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl}amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

RN 446025-65-6 CAPLUS
 CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A





● HCl

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● HCl

RN 446025-66-7 CAPLUS
 CN Benzenepropanoic acid, 5-(aminomethyl)-2-hydroxy-.beta.,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl}amino]-, monohydrochloride (9CI) (CA INDEX NAME)


RN 446025-67-8 CAPLUS
 CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl}amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 2-A



● HCl

PAGE 1-A




PAGE 2-A



RN 446025-68-9 CAPLUS
 CN Benzenepropanoic acid, 3-[([(hexyloxy)carbonyl]aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 446025-69-0 CAPLUS
 CN Benzenepropanoic acid, 3-[(benzoylaminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, propyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 446025-70-3 CAPLUS
 CN Benzenepropanoic acid, 3-[imino{[(2,2,2-trichloroethoxy)carbonyl]amino}methyl]-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 446025-71-4 CAPLUS
 CN Carbamic acid, [(4-hydroxy-3-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]methyl)phenyl]iminomethyl-, hexyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-A


PAGE 2-A




RN 446025-72-5 CAPLUS
 CN Benzamide, N-[(5-(benzoylamino)iminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 446025-73-6 CAPLUS
 CN Benzamide, N-[(2-hydroxy-5-(hydroxylaminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-A

PAGE 2-A



● HCl


RN 446025-74-7 CAPLUS
 CN Carboxic acid, 4-[(benzoylamino)iminomethyl]-2-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]methyl]phenyl ethyl ester (9CI) (CA INDEX NAME)




PAGE 2-A

RN 446025-77-0 CAPLUS
 CN Benzamide, N-[(3-(aminoiminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 446025-78-1 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

RN 446025-79-2 CAPLUS
 CN Benzeneacetamide, 3-(aminomethyl)-N-ethyl- α -[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzyl)amino]- (9CI) (CA INDEX NAME)




RN 446025-90-3 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 446025-90-7 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)- β -(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





RN 446025-91-8 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)- β -(3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl)amino-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 2-A



PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446025-93-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-95-2 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446025-96-3 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446025-97-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446025-98-5 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446025-99-6 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-A



RN 446026-00-2 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-02-4 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[(3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A



PAGE 2-A

RN 446026-03-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[(3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-04-6 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl- (9CI) (CA INDEX NAME)


14 ANSWER 3 OF 23 CARLUS COPYRIGHT 2003 ACS ON STN

(Continued)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS OR STN

(Continued)

PAGE 1-A



PAGE 2-B





PAGE 2-A

1
N

RN 446026-05-7 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl (9CI) (CA INDEX NAME)

RN 446026-06-8 CAPLUS
CN Benzenedipropionic acid, 3-(aminoiminomethyl)-.beta.-[({3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl}amino)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 446026-07-9 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)



RN 446026-08-0 CAPLUS
 CN Benzamide, N-[1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 446026-09-1 CAPLUS
 CN Benzenacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-10-4 CAPLUS
 CN Benzenacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 446026-11-5 CAPLUS
 CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



PAGE 1-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



PAGE 1-A

PAGE 2-A




PAGE 2-A



RN 446026-12-6 CAPLUS
 CN Glycine, 3-{3-(aminiminomethyl)phenyl}-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-beta-alanyl-N-propyl-, ethyl ester (9CI)
 (CA INDEX NAME)


RN 446026-13-7 CAPLUS
 CN Benzamide, N-[1-[5-(aminiminomethyl)-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



PAGE 1-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 446026-14-8 CAPLUS
 CN Benzamide, N-[1-[5-(aminiminomethyl)-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 446026-15-9 CAPLUS
 CN Benzamide, N-[1-[5-(aminiminomethyl)-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446026-16-0 CAPLUS
 CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[(4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 446026-17-1 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 446026-18-2 CAPLUS
 CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

RN 446026-19-3 CAPLUS
 CN Benzenepropanoic acid, 3-[[[(hexyloxy)carbonyl]amino]iminomethyl]-.beta.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-A



RN 446026-20-6 CAPLUS
 CN Benzamide, N-[(2-hydroxy-5-((hydroxyamino)iminomethyl)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

IT 445256-18-8P 445256-19-9P 445256-53-1P
 446026-21-7P 446026-26-2P 446026-27-3P
 446026-28-4P 446026-30-8P 446026-35-3P
 446026-37-5P 446026-39-7P 446026-40-0P
 446026-42-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzamidomethylbenzamides and analogs as factor Xa inhibitors)

RM 445256-18-8 CAPLUS
 CN Benzamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A




● HCl

RN 445256-53-1 CAPLUS
 CN Benzenoacetic acid, 3-(aminoiminomethyl)-,alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 445256-32-6
 CMF C24 H28 N4 O4

RN 445256-19-9 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-A




PAGE 2-A

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

CRN 64-19-7
CMF C2 H4 O2




RN 446026-21-7 CAPLUS
CN Benzenoacetic acid, 3-cyano-,alpha,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, phenyimethyl ester (9CI) (CA INDEX NAME)




RN 446026-26-2 CAPLUS
CN Benzamide, 3-chloro-N-[{5-cyano-2-(phenylmethoxy)phenyl]methyl}-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-27-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-,beta,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}- (9CI) (CA INDEX NAME)




RN 446026-28-4 CAPLUS
CN Benzenepropanamide, 3-cyano-N,N-dimethyl-,beta,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-30-8 CAPLUS
CN Benzamide, N-[{5-cyano-2-(phenylmethoxy)phenyl]ethyl}-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 446026-35-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-,beta,-[{4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino}-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-37-5 CAPLUS
CN Benzamide, N-[{5-cyano-2-(phenylmethoxy)phenyl]methyl}-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 446026-39-7 CAPLUS
CN Benzenepropanoic acid, 3-cyano-2-hydroxy-,beta,-[{3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino}- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 Preparation; THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of phenylamines or phenylamides as anticoagulants)
 RN 445256-32-6 CAPLUS
 CN Benzenesacetic acid, 3-(aminoiminomethyl)-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 PAGE 1-A



PAGE 2-A



● HCl

RN 445256-20-2 CAPLUS
 CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


IT 445256-14-4P 445256-20-2P 445256-36-0P
 445256-38-2P 445256-41-7P 445256-42-8P
 445256-47-3P 445256-53-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of phenylamines or phenylamides as anticoagulants)

RN 445256-14-4 CAPLUS


CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445256-36-0 CAPLUS
 CN Benzenesacetic acid, 3-(aminoiminomethyl)-.alpha.-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 445256-38-2 CAPLUS
 CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 1-A



● HCl

RN 445256-41-7 CAPLUS
 CN Benzamide, N-[(5-(aminomethyl)-2-hydroxyphenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-A



RN 445256-42-8 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-hydroxyphenyl)methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 445256-47-3 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-{[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-A



RN 445256-53-1 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-{[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 445256-32-6
 CMF C24 H28 N4 O4


CM 2

CRN 64-19-7
 CMF C2 H4 O2

IT 445256-18-8P 445256-19-9P 445256-35-9P
 RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of phenylamines or phenylamides as anticoagulants)
 RN 445256-18-8 CAPLUS
 CN Benzamide, N-[(5-cyano-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 445256-19-9 CAPLUS
 CN Benzamide, N-[(5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl)methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A



● HCl

RN 445256-35-9 CAPLUS
 CN Benzeneacetic acid, 3-cyano-,alpha-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)





PAGE 2-A

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002-31402 CAPLUS
 DOCUMENT NUMBER: 136:102190
 TITLE: Preparation of substituted amines to treat Alzheimer's disease
 INVENTOR(S): Maillet, Michel; Hom, Court; Gailunas, Andrea; Jagodzinska, Barbara; Fang, Lawrence Y.; John, Varghese; Frakes, John N.; Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SOURCE: PCT Int. Appl., 651 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002512	A2	20020110	WO 2001-US21012	20010629
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DM, DZ, EC, EE, BE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002128255	A1	20020912	US 2001-896139	20010629
BR 2001012000	A	20030603	BR 2001-12000	20010629
NO 200206199	A	20030221	NO 2002-6199	20021223
PRIORITY APPLN. INFO.:			US 2000-215323P	P 20000630
			US 2000-254736P	P 20001122
			US 2000-255835P	P 20001215
			US 2001-268497P	P 20010213
			US 2001-279779P	P 20010329
			US 2001-295589P	P 20010404
			WO 2001-US21012	W 20010629

OTHER SOURCE(S): MARPAT 136:102190
 GI



II

AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = X R5 = CO, SO2, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH2)0-3-cycloalkyl, etc.], useful in treating Alzheimer's disease and other similar diseases, were prep'd. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalimide in the presence of Et3N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II. The compds. I exhibit an IC50 of < 50 .mu.M against beta-secretase.

IT 388066-79-3P 388066-92-0P 388067-16-1P

388069-73-6P 388069-77-0P 388069-80-5P


388069-84-9P

RN: PAc (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Prep. of substituted amines for treating Alzheimer's disease)


RN 388066-79-3 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-iodophenyl)methyl]amino]propyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-92-0 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-16-1 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-73-6 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-77-0 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-80-5 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1-(3-ethylphenyl)-1-methylethyl)amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388069-84-9 CAPLUS
 CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1-(3-ethylphenyl)cyclopropyl)amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:833867 CAPLUS
 DOCUMENT NUMBER: 135:35774
 TITLE: Preparation of phthalic acid diamides as agricultural and horticultural insecticides
 INVENTOR(S): Tsuchiya, Masanori; Nakao, Hayami; Kohno, Eiji; Nishida, Tatsuki; Furuya, Takanori; Shimizu, Toshiaki; Seo, Akira; Sakata, Kazuyuki; Fujioka, Shinsuke; Kanno, Hideo
 PATENT ASSIGNEE(S): Japan
 SOURCE: U.S. Pat. Appl. Publ., 114 pp., Cont.-in-part of U.S. Ser. No. 198,391, abandoned.
 CODEN: USXXCO


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001041814	A1	20011115	US 1999-250261	19990216
US 6362369	B2	20020326		
US 2003055287	A1	20030320	US 2002-35132	20020104
US 6559341	B2	20030506		

PRIORITY APPLN. INFO.:

JP 1997-339393	A 19971125
JP 1998-51351	A 19980217
US 1998-198391	B2 19981124
US 1999-250261	A3 19990216


OTHER SOURCE(S): MARPAT 135:35774
 GI




AB The title compds. [I; R1-R3 = H, CN, cycloalkyl, etc.; X = H, CN, NO₂, etc.; n = 1-4; Y = H, halo, CN, etc.; m = 1-5; Z1, Z2 = O, S] which show excellent activities for controlling injurious insects, were prep'd. Thus, reaction of 3-nitro-2-ethoxycarbonylbenzoyl chloride with 4-chloro-2-methylaniline in the presence of Et₃N in THF followed by treatment of the resulting Et-6-nitro-N-(4-chloro-2-methoxyphenyl)phthalimide with isopropylamine in dioxane afforded I [R1 = iso-Pr, R2 = R3 = H, X = CN, Z1 = Z2 = O] which showed excellent insecticidal effect (100% mortality) against diamondback moth and cotton bollworm. The fluorine-contg. anilines II [R10 = halo, alkyl, alkoxy, CF₃, R20, R30, R40 = H or perfluoroalkyl; provided that at least one of R20-R40 is not H atom, and that R30 is neither a pentafluoroethyl nor a n-heptafluoropropyl when R10 = F and each of R20 and R40 = H], useful as a starting material for said phthalic acid diamides were also

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 ACCESSION NUMBER: 2001:833867 CAPLUS
 DOCUMENT NUMBER: 135:35774
 TITLE: Preparation of phthalic acid diamides as agricultural and horticultural insecticides
 INVENTOR(S): Tsuchiya, Masanori; Nakao, Hayami; Kohno, Eiji; Nishida, Tatsuki; Furuya, Takanori; Shimizu, Toshiaki; Seo, Akira; Sakata, Kazuyuki; Fujioka, Shinsuke; Kanno, Hideo
 PATENT ASSIGNEE(S): Japan
 SOURCE: U.S. Pat. Appl. Publ., 114 pp., Cont.-in-part of U.S. Ser. No. 198,391, abandoned.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:



RN 226968-04-4 CAPLUS
 CN Benzamide, N-(4-(trifluoromethyl)phenyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 226968-06-5 CAPLUS
 CN Benzamide, N-[4-(difluoromethoxy)-2-methylphenyl]-2-nitro-6-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 226971-91-1 CAPLUS
 CN Benzamide, 3-iodo-N-[2-methyl-4-(pentafluoroethyl)phenyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 1265850 A2 20021218 EP 2001-924277 20010320
 WO 2001070671 A3 20020214
 W: AE, AG, AL, AM, AR, AU, NZ, BN, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MP, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, A1, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN


ACCESSION NUMBER: 2001:713282 CAPLUS
 DOCUMENT NUMBER: 135:272754
 TITLE: Preparation of insecticidal anthranilamides
 INVENTOR(S): Lahm, George P.; Myers, Brian J.; Selby, Thomas P.; Stevenson, Thomas M.
 PATENT ASSIGNEE(S): E.I. Du Pont de Nemours and Company, USA
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXX02

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070671	A2	20010927	WO 2001-US9338	20010320
WO 2001070671	A3	20020214		
W: AE, AG, AL, AM, AR, AU, NZ, BN, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MP, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, A1, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 2001-924277	A2	20021218	EP 2001-924277	20010320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BR 2001009757	A	20030204	BR 2001009757	20010320


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:272754
 GI




AB The title compds. [I; A, B = O, S; J = substituted Ph, naphthyl, (un)substituted 5-6 membered heteroarom., arom. 8-10 membered fused heterocyclic ring; n = 1-4; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, alkoxy, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, halo, etc.], useful for controlling arthropods, were prep'd. E.g., a multi-step

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 synthesis of II which showed excellent level of plant protection (10% or less feeding damage) in test with diamondback moth (DBM), was given.
 IT 362635-67-4P 362635-68-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of insecticidal anthranilamides)
 RN 362635-67-4 CAPLUS
 CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[(2-(1-pyrrolidinylcarbonyl)-4-(trifluoromethyl)benzoyl)amino]- (9CI) (CA INDEX NAME)




RN 362635-68-5 CAPLUS
 CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[(2-(1-pyrrolidinylcarbonyl)-5-(trifluoromethyl)benzoyl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001-300239 CAPLUS
 DOCUMENT NUMBER: 134:252153
 TITLE: Preparation of benzamides as inhibitors of factor Xa
 INVENTOR(S): Zhu, Bing-yan; Zhang, Pengjie; Wang, Liangyan; Huang, Wenrong; Goldman, Eric; Li, Wenhai; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 224 pp.
 CODEN: PIXHD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010609		
W: A1, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, XZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UN, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TZ, TM				
W: A2, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, XZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UN, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TZ, TM				
W: A3, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1216228	A2	20020626	EP 2000-963452	20000915
R: A1, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014076	A	20021015	BR 2000-14076	20000915
JP 2003509406	T2	20030311	JP 2001-523368	20000915
NO 200201229	A	20020521	NO 2002-1229	20020312
PRIORITY APPLN. INFO.:	US 1999-154332P	P 19990917		
OTHER SOURCE(S):	HARPAT 134:252153		US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915




L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:457084 CAPLUS
 DOCUMENT NUMBER: 138:122298
 TITLE: Recognition-induced control and acceleration of a pyrrole Diels-Alder reaction. [Erratum to document cited in Cl135:5280]
 AUTHOR(S): Baines, R.; Babiloni, M. S.; Hayes, W.; Philp, D.
 CORPORATE SOURCE: School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
 SOURCE: Tetrahedron Letters (2001), 42(27), 4595
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: Figure 1 appeared in place of Figure 2 on page 2378; the correct version of Figure 2 is given.
 IT 341991-10-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (hydrogen bonding recognition-induced control and acceleration of pyrrole Diels-Alder reaction (Erratum))
 RN 341991-10-4 CAPLUS
 CN 4,7-imino-2H-isindole-2-propanoic acid, 1,3,3a,4,7,7a-hexahydro-8-[3-([methyl(3-methylphenyl)amino]carbonyl)benzoyl]-1,3-dioxo-, methyl ester, (3aR,4R,7S,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


AB: The title compds. AQDEGJ (A = alkyl, cycloalkyl, (un)substituted Ph, etc.; Q = a direct link, CH₂, CO, etc.; D = a direct link, (un)substituted Ph, naphthyl, etc.; E = a direct link, O, alkyl, etc.; G = alkenylene, cycloalkylene, alkylene, etc.; J = a direct link, O, S, etc.; X = a (un)substituted Ph, naphthyl, heterocycl, etc.) having activity against mammalian factor Xa (no data), and useful in vitro or in vivo for preventing or treating coagulation disorders, were prep'd. E.g., a 4-step synthesis of the benzamide I was given.
 IT 330942-39-6 330942-39-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of benzamides as inhibitors of factor Xa)
 RN 330942-38-6 CAPLUS
 CN Benzamide, N-(5-bromo-2-pyridinyl)-2-[(4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)



RN 330942-39-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-(1-pyrrolidinylcarbonyl)benzoyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)



L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

2001:177305 CAPLUS

135:5288

TITLE: Recognition-induced control and acceleration of a pyrrole Diels-Alder reaction
AUTHOR(S): Bennes, R.; Babloni, M. S.; Hayes, W.; Philp, D.
CORPORATE SOURCE: School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
SOURCE: Tetrahedron Letters (2001), 42(12), 2377-2380
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal Article
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:5288

AB The formation of two hydrogen bonds between an amidopyridine and a carboxylic acid controls the stereochemical outcome and significantly accelerates the rate of the Diels-Alder cycloaddn. between a benzylpyrrole and a maleimide.


IT 341991-10-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (hydrogen bonding recognition-induced control and acceleration of pyrrole Diels-Alder reaction)

RN 341991-10-4 CAPLUS

CN 4,7-Imino-2H-isindole-2-propanoic acid, 1,3,3a,4,7,7a-hexahydro-8-[3-[(methyl[3-methylphenyl]amino)carbonyl]benzoyl]-1,3-dioxo-, methyl ester, (3aR,4R,7S,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:355614 CAPLUS

DOCUMENT NUMBER: 131:31808

TITLE: Preparation of phthalic acid diamides as agricultural

and horticultural insecticides

INVENTOR(S): Toshihiko, Mori; Nakao, Hayami; Kohno, Eiji; Michio, Tatsuki; Furuya, Takanori; Shimizu, Toshiaki; Seo, Akira; Sakata, Kazuyuki; Fujioka, Shinsuke; Kanno, Hideo

PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 237 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 919542	A2	19990602	EP 1998-122107	19981123
EP 919542	A3	20000412		
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100, R101, R102, R103, R104, R105, R106, R107, R108, R109, R110, R111, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122, R123, R124, R125, R126, R127, R128, R129, R130, R131, R132, R133, R134, R135, R136, R137, R138, R139, R140, R141, R142, R143, R144, R145, R146, R147, R148, R149, R150, R151, R152, R153, R154, R155, R156, R157, R158, R159, R160, R161, R162, R163, R164, R165, R166, R167, R168, R169, R170, R171, R172, R173, R174, R175, R176, R177, R178, R179, R180, R181, R182, R183, R184, R185, R186, R187, R188, R189, R190, R191, R192, R193, R194, R195, R196, R197, R198, R199, R200, R201, R202, R203, R204, R205, R206, R207, R208, R209, R210, R211, R212, R213, R214, R215, R216, R217, R218, R219, R220, R221, R222, R223, R224, R225, R226, R227, R228, R229, R230, R231, R232, R233, R234, R235, R236, R237, R238, R239, R240, R241, R242, R243, R244, R245, R246, R247, R248, R249, R250, R251, R252, R253, R254, R255, R256, R257, R258, R259, R260, R261, R262, R263, R264, R265, R266, R267, R268, R269, R270, R271, R272, R273, R274, R275, R276, R277, R278, R279, R280, R281, R282, R283, R284, R285, R286, R287, R288, R289, R290, R291, R292, R293, R294, R295, R296, R297, R298, R299, R300, R301, R302, R303, R304, R305, R306, R307, R308, R309, R310, R311, R312, R313, R314, R315, R316, R317, R318, R319, R320, R321, R322, R323, R324, R325, R326, R327, R328, R329, R330, R331, R332, R333, R334, R335, R336, R337, R338, R339, R340, R341, R342, R343, R344, R345, R346, R347, R348, R349, R350, R351, R352, R353, R354, R355, R356, R357, R358, R359, R360, R361, R362, R363, R364, R365, R366, R367, R368, R369, R370, R371, R372, R373, R374, R375, R376, R377, R378, R379, R380, R381, R382, R383, R384, R385, R386, R387, R388, R389, R390, R391, R392, R393, R394, R395, R396, R397, R398, R399, R400, R401, R402, R403, R404, R405, R406, R407, R408, R409, R410, R411, R412, R413, R414, R415, R416, R417, R418, R419, R420, R421, R422, R423, R424, R425, R426, R427, R428, R429, R430, R431, R432, R433, R434, R435, R436, R437, R438, R439, R440, R441, R442, R443, R444, R445, R446, R447, R448, R449, R450, R451, R452, R453, R454, R455, R456, R457, R458, R459, R460, R461, R462, R463, R464, R465, R466, R467, R468, R469, R470, R471, R472, R473, R474, R475, R476, R477, R478, R479, R480, R481, R482, R483, R484, R485, R486, R487, R488, R489, R490, R491, R492, R493, R494, R495, R496, R497, R498, R499, R500, R501, R502, R503, R504, R505, R506, R507, R508, R509, R510, R511, R512, R513, R514, R515, R516, R517, R518, R519, R520, R521, R522, R523, R524, R525, R526, R527, R528, R529, R530, R531, R532, R533, R534, R535, R536, R537, R538, R539, R540, R541, R542, R543, R544, R545, R546, R547, R548, R549, R550, R551, R552, R553, R554, R555, R556, R557, R558, R559, R5510, R5511, R5512, R5513, R5514, R5515, R5516, R5517, R5518, R5519, R5520, R5521, R5522, R5523, R5524, R5525, R5526, R5527, R5528, R5529, R5530, R5531, R5532, R5533, R5534, R5535, R5536, R5537, R5538, R5539, R55310, R55311, R55312, R55313, R55314, R55315, R55316, R55317, R55318, R55319, R55320, R55321, R55322, R55323, R55324, R55325, R55326, R55327, R55328, R55329, R55330, R55331, R55332, R55333, R55334, R55335, R55336, R55337, R55338, R55339, R55340, R55341, R55342, R55343, R55344, R55345, R55346, R55347, R55348, R55349, R55350, R55351, R55352, R55353, R55354, R55355, R55356, R55357, R55358, R55359, R55360, R55361, R55362, R55363, R55364, R55365, R55366, R55367, R55368, R55369, R55370, R55371, R55372, R55373, R55374, R55375, R55376, R55377, R55378, R55379, R55380, R55381, R55382, R55383, R55384, R55385, R55386, R55387, R55388, R55389, R55390, R55391, R55392, R55393, R55394, R55395, R55396, R55397, R55398, R55399, R553100, R553101, R553102, R553103, R553104, R553105, R553106, R553107, R553108, R553109, R553110, R553111, R553112, R553113, R553114, R553115, R553116, R553117, R553118, R553119, R553120, R553121, R553122, R553123, R553124, R553125, R553126, R553127, R553128, R553129, R553130, R553131, R553132, R553133, R553134, R553135, R553136, R553137, R553138, R553139, R553140, R553141, R553142, R553143, R553144, R553145, R553146, R553147, R553148, R553149, R553150, R553151, R553152, R553153, R553154, R553155, R553156, R553157, R553158, R553159, R553160, R553161, R553162, R553163, R553164, R553165, R553166, R553167, R553168, R553169, R553170, R553171, R553172, R553173, R553174, R553175, R553176, R553177, R553178, R553179, R553180, R553181, R553182, R553183, R553184, R553185, R553186, R553187, R553188, R553189, R553190, R553191, R553192, R553193, R553194, R553195, R553196, R553197, R553198, R553199, R553200, R553201, R553202, R553203, R553204, R553205, R553206, R553207, R553208, R553209, R553210, R553211, R553212, R553213, R553214, R553215, R553216, R553217, R553218, R553219, R553220, R553221, R553222, R553223, R553224, R553225, R553226, R553227, R553228, R553229, R553230, R553231, R553232, R553233, R553234, R553235, R553236, R553237, R553238, R553239, R553240, R553241, R553242, R553243, R553244, R553245, R553246, R553247, R553248, R553249, R553250, R553251, R553252, R553253, R553254, R553255, R553256, R553257, R553258, R553259, R553260, R553261, R553262, R553263, R553264, R553265, R553266, R553267, R553268, R553269, R553270, R553271, R553272, R553273, R553274, R553275, R553276, R553277, R553278, R553279, R553280, R553281, R553282, R553283, R553284, R553285, R553286, R553287, R553288, R553289, R553290, R553291, R553292, R553293, R553294, R553295, R553296, R553297, R553298, R553299, R553300, R553301, R553302, R553303, R553304, R553305, R553306, R553307, R553308, R553309, R553310, R553311, R553312, R553313, R553314, R553315, R553316, R553317, R553318, R553319, R553320, R553321, R553322, R553323, R553324, R553325, R553326, R553327, R553328, R553329, R553330, R553331, R553332, R553333, R553334, R553335, R553336, R553337, R553338, R553339, R553340, R553341, R553342, R553343, R553344, R553345, R553346, R553347, R553348, R553349, R553350, R553351, R553352, R553353, R553354, R553355, R553356, R553357, R553358, R553359, R553360, R553361, R553362, R553363, R553364, R553365, R553366, R553367, R553368, R553369, R553370, R553371, R553372, R553373, R553374, R553375, R553376, R553377, R553378, R553379, R553380, R553381, R553382, R553383, R553384, R553385, R553386, R553387, R553388, R553389, R553390, R553391, R553392, R553393, R553394, R553395, R553396, R553397, R553398, R553399, R553400, R553401, R553402, R553403, R553404, R553405, R553406, R553407, R553408, R553409, R553410, R553411, R553412, R553413, R553414, R553415, R553416, R553417, R553418, R553419, R553420, R553421, R553422, R553423, R553424, R553425, R553426, R553427, R553428, R553429, R553430, R553431, R553432, R553433, R553434, R553435, R553436, R553437, R553438, R553439, R553440, R553441, R553442, R553443, R553444, R553445, R553446, R553447, R553448, R553449, R553450, R553451, R553452, R553453, R553454, R553455, R553456, R553457, R553458, R553459, R553460, R553461, R553462, R553463, R553464, R553465, R553466, R553467, R553468, R553469, R553470, R553471, R553472, R553473, R553474, R553475, R553476, R553477, R553478, R553479, R553480, R553481, R553482, R553483, R553484, R553485, R553486, R553487, R553488, R553489, R553490, R553491, R553492, R553493, R553494, R553495, R553496, R553497, R553498, R553499, R553500, R553501, R553502, R553503, R553504, R553505, R553506, R553507, R553508, R553509, R553510, R553511, R553512, R553513, R553514, R553515, R553516, R553517, R553518, R553519, R553520, R553521, R553522, R553523, R553524, R553525, R553526, R553527, R553528, R553529, R553530, R553531, R553532, R553533, R553534, R553535, R553536, R553537, R553538, R553539, R553540, R553541, R553542, R553543, R553544, R553545, R553546, R553547, R553548, R553549, R553550, R553551, R553552, R553553, R553554, R553555, R553556, R553557, R553558, R553559, R553560, R553561, R553562, R553563, R553564, R553565, R553566, R553567, R553568, R553569, R553570, R553571, R553572, R553573, R553574, R553575, R553576, R553577, R553578, R553579, R553580, R553581, R553582, R553583, R553584, R553585, R553586, R553587, R553588, R553589, R553590, R553591, R553592, R553593, R553594, R553595, R553596, R553597, R553598, R553599, R553600, R553601, R553602, R553603, R553604, R553605, R553606, R553607, R553608, R553609, R553610, R553611, R553612, R553613, R553614, R553615, R553616, R553617, R553618, R553619, R553620, R553621, R553622, R553623, R553624, R553625, R553626, R553627, R553628, R553629, R553630, R553631, R553632, R553633, R553634, R553635, R553636, R553637, R553638, R553639, R553640, R553641, R553642, R553643, R553644, R553645, R553646, R553647, R553648, R553649, R553650, R553651, R553652, R553653, R553654, R553655, R553656, R553657, R553658, R553659, R553660, R553661, R553662, R553663, R553664, R553665, R553666, R553667, R553668, R553669, R553670, R553671, R553672, R553673, R553674, R553675, R553676, R553677, R553678, R553679, R553680, R553681, R553682, R553683, R553684, R553685, R553686, R553687, R553688, R553689, R553690, R553691, R553692, R553693, R553694, R553695, R553696, R553697, R553698, R553699, R553700, R553701, R553702, R553703, R553704, R553705, R553706, R553707, R553708, R553709, R553710, R553711, R553712, R553713, R553714, R553715, R553716, R553717, R553718, R553719, R553720, R553721, R553722, R553723, R553724, R553725, R553726, R553727, R553728, R553729, R553730, R553731, R553732, R553733, R553734, R553735, R553736, R553737, R553738, R553739, R553740, R553741, R553742, R553743, R553744, R553745, R553746, R553747, R553748, R553749, R553750, R553751, R553752, R553753, R553754, R553755, R553756, R553757, R553758, R553759, R553760, R553761, R553762, R553763, R553764, R553765, R553766, R553767, R553768, R553769, R553770, R553771, R553772, R553773, R553774, R553775, R553776, R553777, R553778, R553779, R553780, R553781, R553782, R553783, R553784, R553785, R553786, R553787, R553788, R553789, R553790, R553791, R553792, R553793, R553794, R553795, R553796, R553797, R553798, R553799, R553800, R553801, R553802, R553803, R553804, R553805, R553806, R553807, R553808, R553809, R553810, R5				

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Benzamide, 3-iodo-N-[2-methyl-4-(pentafluoroethyl)phenyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 19981779474 CAPLUS
 DOCUMENT NUMBER: 130:76175
 TITLE: Amide and urea derivatives as ACAT inhibitors and antiarteriosclerotics
 INVENTOR(S): Yoshida, Akira; Oda, Kozo; Kasai, Takashi; Shimada, Kamil; Komina, Hiroshi; Hayakawa, Ichio; Ishihara, Sadao; Koga, Teiichiro; Kitazawa, Eiichi; Tokui, Taro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 127 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 10316562 A2 19981202 JP 1998-62571 19980313
 PRIORITY APPLN. INFO.: JP 1997-61379 19970314
 OTHER SOURCE(S): MARPAT 130:76175
 GI



AB Amide and urea derivs. (I): R1 = alkyl; R2a, R2b, R2c, R2d = H, substituted alkyl, nitro, substituted amino, (protected)OH, alkoxy, cyano, between R2a and R2b with -O-(CH2)m-O- (m = 1-3), alkylthio, alkylsulfinyl, alkylsulfonyl, halogen; R3 = alkyl; R4 = amiocarbonyl, aminocarbonylmethyl and their pharmacol. acceptable salts are claimed as ACAT inhibitors and antiarteriosclerotics. The ACAT inhibitory action of I was tested, and pharmaceutical hard capsules of I were formulated.
 IT 189092-10-28 RRL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPP (Synthetic preparation); THU (Therapeutic use); BICL (Biological study); PREP (Preparation); USES (Uses); (amide and urea derivs. as ACAT inhibitors and antiarteriosclerotics)
 RN 189092-10-2 CAPLUS
 CN 1-(2-(1,1-dimethylethyl)-5-[(methylanino)carbonyl]phenyl)-2,4-dimethoxy-.beta.-pentyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 19981509180 CAPLUS

DOCUMENT NUMBER: 129:161414
 TITLE: Preparation of benzamidine derivatives as anti-coagulants
 INVENTOR(S): Takayana, Masaru; Sagi, Kazuyuki; Nakagawa, Tadakiyo; Yamashita, Masahiro; Kayahara, Takashi; Takehana, Shunji et al.
 PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
 SOURCE: PCT Int. Appl., 453 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 9831661 A1 19980723 WO 1998-17176 19980119
 W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, EE, ES, FI, GR, HU, IE, IL, IS, IT, JP, ME, MG, MK, MT, MU, NK, NL, NO, NZ, PL, PT, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, XZ, MD, RU, TJ, TQ, TW, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
 AU 9854975 A1 19980807 AU 1998-54975 19980119
 AU 731819 B2 20010405
 EP 976722 A1 20000202 EP 1998-900422 19980119
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI
 PRIORITY APPLN. INFO.: JP 1997-6783 A 19970117
 JP 1997-194502 A 19970718
 JP 1997-331887 A 19971202
 WO 1998-JE176 W 19980119
 OTHER SOURCE(S): MARPAT 129:161414
 GI




AB The title compds. I [L = CH2CH2, NWCOCH2, etc., W = H, alkyl, etc.; Y = CH2CH, CONH, etc.; Z = H, alkyl, halo, etc.; when L is CH2CH2, Y is benzoyl, cinnamoyl, etc., having substituents; further details on Y are given] are prep'd. These compds. show anticoagulant effects based on their excellent effects of inhibiting activated blood coagulation factor X, which makes them useful as anticoagulants. In in vitro tests for the inhibition of activated blood coagulation factor X, compds. of this invention showed pIC50 values of 5.5 to 8.1.

L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 IT 210961-74-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prpns. of benzamidine derivs. as anticoagulants)
 RN 210961-74-3 CAPLUS
 CN Benzamide, N-[(IR)-1-[(3-(aminoiminomethyl)phenoxy)methyl]-2-phenylethyl]-4-(1-pyrrolidinylcarbonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210961-73-2
CMF C28 H30 N4 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 1997:317732 CAPLUS
 126:293189
 DOCUMENT NUMBER:
 TITLE: Preparation of N-(carbamoylphenyl)alkanamides and analogs as cholesterol acyltransferase inhibitors
 INVENTOR(S): Yoshida, Akira; Oda, Kozu; Kasai, Takashi; Shimada, Kousai; Koga, Hiroshi; Hayakawa, Ichiro; Ishihara, Sadao; Koga, Teiichiro; Kitazawa, Eiichi; Tokui, Taro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 280 pp.
 CODEN: EPXXDW


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 763524	A1	19970319	EP 1996-306781	19960918
EP 763524	B1	20000823		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2185737	AA	19970319	CA 1996-2185737	19960917
NO 9603896	A	19970319	NO 1996-3896	19960917
AU 9665659	A1	19970320	AU 1996-65659	19960917
AU 712467	B2	19991104		
ZA 9607840	A	19970407	ZA 1996-7840	19960917
RU 2128165	C1	19970427	RU 1996-118358	19960917
09143137	A2	19970503	JP 1996-246401	19960918
CA 2185738	A	19980128	CA 1996-119249	19960918
US 5880147	A	19990309	US 1996-715589	19960918
AT 195724	E	20000915	AT 1996-306781	19960918
ES 2151540	T3	20010101	ES 1996-306781	19960918
US 6040339	A	20000321	US 1998-86402	19980528
HK 1011349	A1	20010119	HK 1998-112513	19981130
PRIORITY APPLN. INFO.:			JP 1995-238042	A 19950918
			US 1996-715589	A3 19960918
OTHER SOURCE(S):			MARPAT 126:293189	
GI				



AB RCH(R1)CH2(NH)nCONHR3 (I; R = (un)substituted Ph; R1,R3 = alkyl; Z = 1,2-phenylene further substituted by AlCONR5aR5b, AlCN, A2NR7CONR5aR5b, etc.; A1 = bond or alk(en)ylene; A2 = alk(en)ylene; R5a,R5b = H, alkyl, etc.)


L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 alkoxyl, etc.; R7 = H or alkyn (n = 0 or 1) were prepd. Thus, 2,4-(MeO)C6H3CHO was condensed with CH2(CO2Et)2 and the BuCH2MgBr-alkylated product converted in 2 steps to 2,4-(MeO)C6H3CH(CH2Bu)CH2CO2H which was amidated by Me 3-amino-4-tert-butylbenzoate (prpns. given) to give, in 2 addnl. steps, title compd. II. Data for 1,2-phenylene activity of I were given.
 IT 19960910-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prpns. of N-(carbamoylphenyl)alkanamides and analogs as cholesterol acyltransferase inhibitors)
 RN 189092-10-2 CAPLUS
 CN Benzenepropanamide, N-[2-(1,1-dimethylethyl)-5-[(methylamino)carbonyl]phenyl]-2,4-dimethoxy-.beta.-pentyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 1996:202914 CAPLUS
 124:277951
 DOCUMENT NUMBER:
 TITLE: Nonpeptide Cholecystokinin-B/Gastrin Receptor Antagonists Based on Bicyclic, Heteroaromatic Skeletons
 AUTHOR(S): Kalindjian, S. Barret; Buck, Ildiko M.; Davies, Jonathan M. R.; Dunstone, David J.; Hudson, Martin L.; Low, Caroline M. R.; McDonald, Iain M.; Pether, Michael J.; Steel, Katherine J. M.; et al.
 CORPORATE SOURCE: James Black Foundation, London, SE24 9JS, UK
 SOURCE: Journal of Medicinal Chemistry (1996), 39(9), 1806-15
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of potent and selective cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane (BCO) skeleton which have recently been described were found to show species-dependent behavior when examined in rat and dog models. We now report the discovery of compds. in which the BCO skeleton has been replaced with bicyclic, heteroaromatic frameworks, such as a 5,6-disubst. benzimidazole or imidazolidine. These ligands maintain the affinity and selectivity profile of the previous compds. in vitro but show a much more consistent behavior pattern *in vivo*. Representative examples of this class of compd. have been shown to inhibit pentagastrin-stimulated acid secretion when administered i.v. at doses of 0.1 .mu.mol kg⁻¹ or less.

IT 167990-56-9P
 RL: SFN (Synthetic preparation); PREP (Preparation)
 (non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroarom. skeletons)
 RN 167990-56-9 CAPLUS
 CN D-Proline, 1-[[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1996:25340 CAPLUS
 DOCUMENT NUMBER: 124:56894
 TITLE: Polyimide Formation through the Palladium-Mediated Carbonylation and Coupling of Bis(o-iodo amides) and Diamines
 AUTHOR(S): Paul, Robert J.; Tunney, Scott E.; Wilson, B. David
 CORPORATE SOURCE: Eastman Kodak Company, Rochester, NY, 14650-1705, USA
 SOURCE: Macromolecules (1996), 29(3), 1014-20
 CODEN: MAMOEB; ISSN: 0024-9297
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Reactions between bis(o-iodo amides) and diamines in the presence of a palladium catalyst and a base at elevated (90 psig) carbon monoxide (CO) pressures give intermediate poly(amic amide) polymers which can be thermally ring-closed to the fully imidized polyimides. Model studies indicate that competing side reactions are suppressed and the intermediate o-diamide is stabilized when diisopropylamides are used.
 IT 171261-72-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (model reaction products; polyimide formation through the Pd-mediated carbonylation and coupling of bis(o-iodo amides) and diamines)
 RN 171261-72-6 CAPLUS
 CN Benzamide, N-phenyl-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1995:1005479 CAPLUS
 DOCUMENT NUMBER: 124:176900
 TITLE: Protein Structure-Based Design of Combinatorial Libraries: Discovery of Non-Peptide Binding Elements to Src SH3 Domain
 AUTHOR(S): Combs, Andrew P.; Kapoor, Tarun M.; Feng, Sibo; Chen, James K.; Dauda-Snow, Lydia F.; Schreiber, Stuart L.
 CORPORATE SOURCE: Howard Hughes Medical Institute, Harvard University, Cambridge, MA, 02138, USA
 SOURCE: Journal of the American Chemical Society (1996), 118(1), 287-8
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB An approach to the discovery of cell permeable ligands to protein receptors is described. By example, the 3-dimensional structures of SH3-peptide complexes determined by multidimensional NMR, a solid phase, encoded combinatorial synthesis was rationally designed to deliver nonpeptide binding elements to the site of a key specificity-pocket in SH3 domains. Fifteen ligands to the SH3 domain from the protein tyrosine kinase Src were selected from a pool of >1,000,000 spatially sepd. mols. These were resynthesized and individually analyzed for their ability to bind to the Src SH3 domain. They were shown to be among the highest affinity SH3 ligands known, and they are the first SH3 ligands to use nonpeptide binding elements. The strategy used in this study is expected to be applicable to the discovery of ligands to proteins in general in general.
 IT 173911-61-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (protein structure-based design of combinatorial libraries discovery of nonpeptide binding elements to Src SH3 domain)

RN 173911-61-0 CAPLUS
 CN L-Prolinamide, 1-[3-[[4-(aminomethyl)phenyl]methyl][4-[[3-nitro-5-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]carbonyl]benzoyl]amino]methyl]cyclohexyl]carbonyl]amino]-1-oxopropropyl]-L-prolyl-L-leucyl-L-prolyl-L-prolyl-L-leucyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:1005429 CAPLUS
 DOCUMENT NUMBER: 123:256710
 TITLE: Preparation of gastrin and CCK receptor ligands
 INVENTOR(S): Kaladjian, Sarkis Barret; Steel, Katherine Isobel
 Mary; Pether, Michael John; Davies, Jonathan Michael
 Richard; Low, Caroline Minli Rachel; Hudson, Martin
 Lynn Buck, Ildiko Maria; McDonald, Iain Mair
 Dunstone, David John; Tozer, Matthew John
 James Black Foundation Ltd., UK
 PATENT ASSIGNEE(S): PCT Int. Appl., 124 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504726	A2	199502116	WO 1994-GB1741	19940809
WO 9504740	A3	19950803		
W: AM, AT, BE, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9473478	A1	19950228	AU 1994-73478	19940809
AU 682051	B2	19970918		
EP 720601	A1	19960710	EP 1994-922318	19940809
EP 720601	B1	20001025		
R: AM, AT, BE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09502430	T2	19970311	JP 1994-506306	19940809
HU 75301	A2	19970528	HU 1996-322318	19940809
AT 197146	E	20010115	AT 1994-322318	19940809
ES 2152989	T3	20010116	ES 1994-322318	19940809
PL 981782	A1	20010228	PL 1994-332960	19940809
ZA 945539	A1	19960212	ZA 1994-5998	19940810
GB 2200539	A1	19960103	GB 1995-2503	19950209
WO 9523949	A1	19951103	WO 1995-GB1194	19950525
W: AM, AT, BE, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9525342	A1	19951221	AU 1995-25342	19950525
EP 763026	A1	19970319	EP 1995-919561	19950525
EP 763026	B1	20030326		
R: AM, AT, BE, CH, DE, DK, ES, FR, GR, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504525	T2	199805016	JP 1995-500483	19950525
AT 235110	E	200304115	AT 1995-919561	19950525
NO 960048	A	199611236	ZA 1995-4315	19950526
NO 9600488	A	199603115	NO 1996-488	19960206
FI 9600572	A	19960207	FI 1996-572	19960207
US 5795907	A	19980818	US 1996-583008	19960318
US 5912260	A	19990615	US 1996-737725	19961219
US 5919829	A	19990706	US 1998-64849	19980423


PRIORITY APPLN. INFO.:

GB 1993-16508 A 19930810


GB 1994-10688 A 19940527

WO 1994-GB1741 W 19940809

PAGE 1-B



L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 GB 1995-2503 A 19950209
 WO 1995-GB1194 W 19950525
 OTHER SOURCE(S): MARPAT 123:256711
 GI



II

AB Title compds. [e.g. I]: A = atoms to complete a bicyclic ring system; R1 = halo, NH2, cyano, OH, alkyl, CO2H, etc.; 1 of X, W = CO and the other = CO, SO, SO2; Y = NR3R4, hydrocarboxylic, etc.; R3 = H, hydrocarbonyl, etc.; R4 = 1-alkyl, (un)esterified CH2CO2H; Z = OH, alkoxyl, OPh, (un)substituted NH2, NH2R, etc.; R = H, cyano, alkyl, CO2H, CO2H, etc.; Z1 = alkylene, methylene, etc. Thus, the cyclohexene anhydride was converted in 6 steps to indole-5,6-dicarboxylic anhydride which was amidated by adamantan-1-methylamine and the product amidated by (S)-3-(PhNH2CO2C)2C6H3NHC(OH)(NH2)CH2Ph (prep., given) to give, in 2 addnl. steps, title compd. (S)-II the di-N-methyl-D-glucamine salt of which had pKa of 9.4 for binding at mouse cortex CCK8 receptors in vitro.

IT 167990-56-9P 167990-57-0P 167990-58-1P
 167990-59-2P 167990-62-7P 167990-63-8P
 167990-65-0P 167990-66-1P 167990-67-2P
 167990-68-3P 167990-69-4P 167990-70-7P
 167990-71-8P 167990-72-9P 167990-75-2P
 167990-76-3P 167990-80-9P 167990-81-0P
 167991-75-5P 167991-76-6P 167991-77-7P
 167991-78-8P 167991-93-7P 167991-94-8P
 167993-49-9P 167993-50-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SIR (Synthetic preparation); THU (Therapeutic use); BIOC (Biological activity); PREP (Preparation); USES (Uses); (prep. of gastrin and CCK receptor ligands)

RN 167990-56-9 CAPLUS

CN D-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167990-57-0 CAPLUS
 D-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-56-9
 CMF C28 H32 N2 O4


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-58-1 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN L-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-59-2 CAPLUS
 CN L-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-58-1
 CMF C28 H32 N2 O4


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-62-7 CAPLUS


L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN D-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-63-8 CAPLUS
 CN D-Proline, 1-[3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167990-65-0 CAPLUS
 CN D-Proline, 1-[3-[(methyltricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-66-1 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN D-Proline, 1-[3-[(methyl(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino)carbonyl]-2-naphthalenyl]carbonyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-65-0
CMF C29 H34 N2 O4


Absolute stereochemistry.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-67-2 CAPLUS
 CN D-Alanine, N-[1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 167990-68-3 CAPLUS
 CN Glycine, N-[1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167990-69-4 CAPLUS
 CN L-Alanine, N-[1-[(3-[(methyl(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino)carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167990-70-7 CAPLUS
 CN L-Alanine, N-[1-[(3-[(methyl(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino)carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)

CM 1

CRN 167990-69-4
CMF C32 H39 N3 O5


Absolute stereochemistry.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-71-8 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Glycine, N-[1-[(3-[(methyl(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino)carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-72-9 CAPLUS
 CN Glycine, N-[1-[(3-[(methyl(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino)carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl- (9CI) (CA INDEX NAME)

CM 1

CRN 167990-71-8
CMF C31 H37 N3 O5


Absolute stereochemistry.



CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167990-75-2 CAPLUS
CN D-Alanine, N-[1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-2-pyrrolidinyl]acetyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 167990-76-3 CAPLUS
CN D-Alanine, N-[1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-L-prolyl], compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 167990-75-2
CMF C32 H39 N3 O5

Absolute stereochemistry.




CM 2
CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167991-75-5 CAPLUS
CN Glycine, N-[1-[(6-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-benzimidazol-5-yl]carbonyl]-D-prolyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167991-76-6 CAPLUS
CN Glycine, N-[1-[(6-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-benzimidazol-5-yl]carbonyl]-D-prolyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167990-80-9 CAPLUS
CN D-Proline, 1-[(4,5-dichloro-2-[2-oxo-2-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]ethyl]benzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167990-81-0 CAPLUS
CN D-Proline, 1-[(4,5-dichloro-2-[2-oxo-2-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]ethyl]benzoyl)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 167990-80-9
CMF C25 H30 Cl2 N2 O4

Absolute stereochemistry.

CRN 167991-75-5
CMF C27 H33 N5 O5


Absolute stereochemistry.



CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167991-77-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 8-[[1-[(6-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-benzimidazol-5-yl]carbonyl]-2-pyrrolidinyl]carbonyl]amino-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167991-78-8 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, (S)-5-[[1-[(6-

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 [[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-1H-benzimidazol-5-yl]carbonyl-2-pyrrolidinyl carbonyl]amino]-1,3-benzenedicarboxylate (2:1) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 167991-77-7
 CMF C33 H35 N5 O7


Absolute stereochemistry.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5


Absolute stereochemistry.



RN 167991-93-7 CAPLUS
 CN D-Alanine, N-[1-[(6-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-indol-5-yl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167991-94-8 CAPLUS
 CN D-Alanine, N-[1-[(6-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-indol-5-yl]carbonyl]-D-prolyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167991-93-7
CMF C29 H36 N4 O5

Absolute stereochemistry.




CM 2

CRN 6284-40-8
CMF C7 H17 N O5


Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 167993-49-9 CAPLUS
 CN L-Alanine, N-[1-[(5-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-indol-6-yl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167993-50-2 CAPLUS
 CN L-Alanine, N-[1-[(5-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-1H-indol-6-yl]carbonyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 167993-49-9
CMF C29 H36 N4 O5

Absolute stereochemistry.




CM 2

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




IT 167992-78-1 167992-79-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep. of gastrin and CCK receptor ligands)
 RN 167992-78-1 CAPLUS
 CN D-Proline, 1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167992-79-2 CAPLUS
 CN D-Alanine, N-[1-[(3-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl)-2-naphthalenyl]carbonyl]-D-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1994:164907 CAPLUS
 DOCUMENT NUMBER: 120:164907
 TITLE: Preparation of proline containing peptide analogs as specific inhibitors of prolyl endopeptidase
 INVENTOR(S): Kobayashi, Koji; Nishii, Kazuhiko; Iwata, Kunio; Uchida, Itsuro
 PATENT ASSIGNEE(S): Nippon Tobacco Sangyo, Japan; Yoshitomi Pharmaceutical
 SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 05201970 A2 19930810 JP 1992-50136 19920124
 PRIORITY APPLN. INFO.: JP 1992-50136 19920124
 OTHER SOURCE(S): MARPAT 120:164907
 GI




AB Title compds. [I]: A = O, NH, CONH, single bond; B = Q-Q2, (CH2)_k, NHCHR1; k = 1-3; R1 = H, lower alkyl; W = 2-oxo-1-pyrrolidinyl, R2C6H4; R2 = H, halo, lower alkyl; X = S, SO, SO2, O, NH2; R = Q3, lower alkyl; I = 0-3; Y, Z = H, halo, lower (fluoro)alkyl, NH2, NO2, OH, lower alkoxy; or Y2 may form (un)satd. 5- or 6-membered ring; n = 1-6] are prep'd. I specifically inhibit decompn. and inactivation of proline-contg. brain hormones and neurotransmitters (TSH-releasing hormone, substance P, neurotensin, and vasopressin) and thus are useful for the improvement of such hormones and neurotransmitters-related diseases and for the prevention and treatment of dementia and amnesia including Alzheimer's disease, directly acting on the core symptoms of dementia. Thus, NaH was stirred with DMSO at 0-degree. for 1 min. and was cold. with THF cooled to -5-degree., and then treated with a soln. of Me3Si in DMSO followed by a soln. of N-tert-butoxycarbonyl-L-prolyl in THF to give, after reacting at 0-degree. for 1 h, (2S)-1-(tert-butoxycarbonyl)-2-(1-epoxyethyl)pyrrolidine. The latter compd. was refluxed with 4-chlorophenol in MeOH contg. NaOMe to give

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of, an intermediate for prolyl endopeptidase inhibitor)
 IT 153451-27-5 CAPLUS
 RN 153451-27-5 CAPLUS
 CN Benzamide, 2-[(2-(1-hydroxy-2-phenoxethyl)-1-pyrrolidinyl)carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 153451-03-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep. of, as prolyl endopeptidase inhibitor)
 IT 153451-03-7 CAPLUS
 CN Benzamide, 5-[(2-(phenoxyacetyl)-1-pyrrolidinyl)carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1992:633813 CAPLUS
 DOCUMENT NUMBER: 117:233813
 TITLE: Exploratory studies of .alpha.-silylamino- and .alpha.-silylamido-2,5-cyclohexadien-1-one SET photochemistry. Methodology for synthesis of functionalized hydroisoquinolines
 AUTHOR(S): Jung, Young Shik; Swartz, William H.; Xu, Wei; Mariano, Patricia S.; Green, Neal J.; Schultz, Arthur G.
 CORPORATE SOURCE: Dep. Chem. Biochem., Univ. Maryland, College Park, MD, 20742, USA
 SOURCE: Journal of Organic Chemistry (1992), 57(22), 6037-47
 DOCUMENT TYPE: CODEN: JOCOEH; ISSN: 0022-3263
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 GI CASREACT 117:233813




AB The electron-transfer (SET) photochem. of selected .alpha.-silylamino and .alpha.-silylamido-2,5-cyclohexadienones, e.g., I, has been explored with the intent of developing a novel and potentially efficient method for functionalized hydroisoquinoline synthesis. These substances, prep'd. by Birch redn., alkylation-oxidn. sequences, were found to undergo 9,10-dicyanoanthracene-SET-sensitized radical cyclization to form hydroisoquinolines, e.g., II, in highly regio- and stereoselective fashion and in modest to good yields. In contrast, the major direct irradn. reaction pathway followed by the .alpha.-silylamido-substituted systems involves type A rearrangement to bicyclic cyclohexenone or cyclohexenol. DSC irradn. of the .alpha.-silylamino analogs, on the other hand, brings about near-exclusively conversion to the corresponding hydroisoquinolines. The synthetic and mechanistic features of this study are described.

IT 143925-63-7P 143925-64-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of)
 RN 143925-63-7 CAPLUS
 CN Benzeneacetamide, 5-hydroxy-N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)-N-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 143925-64-8 CAPLUS
 CN Benzeneacetamide, 3-hydroxy-N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)-N-(trimethylsilyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1992194147 CAPLUS
 DOCUMENT NUMBER: 116194147
 TITLE: Preparation of 1-arylpiperidines-2-carboxaldehydes and analogs as psychoanaleptic agents
 INVENTOR(S): Faraci, W. Stephen; Nagel, Arthur A.; Spencer, Robin W.; Vinick, Fredic J.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 60 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9118891	A1	199111212	WO 1991-US3390	19910515
W, CA, FI, JP, US				
EP 536163	A1	19930414	EP 1991-910005	19910515
EP 536163	A1	19930414	EP 1991-910005	19910515
R, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506442	T2	19930922	JP 1991-509445	19910515
JP 05506442	T2	19930922	JP 1991-509445	19910515
JP 2511605	B2	19960703		
US 5847155	A	19981208	US 1996-592221	19960126
US 5847155	A	19981208	US 1990-532534	19900604
PRIORITY APPLN. INFO.:			WO 1991-US3390	19910515
			US 1993-960374	19930127

OTHER SOURCE(S): MARPAT 116:194147
 GI




AB Title compds. [I; X = S, (CH₂)_n; Y = H, CHO, COCF₃, hydroxalkyl, etc.; Z = 1-fluorenonyl, 2-(1-naphthoyl)phenyl, 2-arylcyclenyl, 2-carbamoylcyclopent(en)yl, etc.; n = 1, 2] were prep. as prolyl endopeptidase inhibitors (no data). Thus, indole-2-carboxylic acid was condensed with ClCO₂CH₂Ph and the product condensed with (S)-(+)pyrrolidinemethanol to give after oxidn., title compd. II.

IT 135382-78-4 RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of, as psychoanaleptic agent)

RN 140486-11-9 CAPLUS
 CN Benzamide, 2-[(2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

Absolute stereochemistry.




RN 140486-12-0 CAPLUS
 CN Benzamide, 2-[(2-formyl-1-pyrrolidinyl)carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 19911514208 CAPLUS
 DOCUMENT NUMBER: 115114208


TITLE: Study of phthalimido chemistry. I. Extension of utility by conversion to the OPCB protecting group
 AUTHOR(S): Astleford, Brett; Weigel, Leland O.
 CORPORATE SOURCE: Chem. Process Res. Dev. Div., Lilly Res. Lab., Indianapolis, IN, 46285, USA
 SOURCE: Tetrahedron Letters (1991), 32(28), 3301-4
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The susceptibility of the phthalimido protecting group to basic and nucleophilic conditions has been overcome by conversion to o-pyrrolidinocarbonylbenzamides (OPCBs). Thus, reaction of phthalimides, e.g. I, with pyrrolidines in THF gave 83-98% OPCBs, e.g. II. The OPCBs are stable to non-equilibrating basic and mild acidic conditions. The OPCB group can be either cleaved to give the amine or converted back to the phthalimide.

IT 135382-78-4 RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep. and intramol. cyclocondensation of, phthalimide from)

RN 135382-78-4 CAPLUS
 CN Benzamide, N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1984:191959 CAPLUS
 DOCUMENT NUMBER: 100491959

TITLE: Organophosphorus compounds. XIX. Synthesis of 2,3-dihydro-1H-1,2-benzazaphophole 2-oxides, variously substituted on nitrogen and phosphorus, by nitrogen-phosphorus cyclization of zwitterionic intermediates

AUTHOR(S): Collins, David J.; Drygala, Peter F.; Swan, John M.
 CORPORATE SOURCE: Dep. Chem., Monash Univ., Clayton, 3168, Australia
 SOURCE: Australian Journal of Chemistry (1983), 36(12), 2517-36
 CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:191959
 GI



AB 2-Phenyl-2,3-dihydro-1H-1,2-benzazaphophole 2-oxide (I; R = H) was prepd. by thermolysis of the corresponding zwitterionic aminophosphinic acid (II) or II.HCl. Thermolysis of Me or Et (2-aminobenzyl)phenylphosphinate was accompanied by intermol. O.fwdarw. N-transalkylation to give, after cyclization, I (R = Me, Et, resp.). Reaction of 2-phthalimidobenzyl bromide with MeI(OEt)_2 gave Et (2-phthalimidobenzyl)methylphosphinate (III). Hydrolysis of III afforded 2-methyl-2,3-dihydro-1H-1,2-benzazaphophole 2-oxide (IV). 1-Methyl-2,3-dihydro-1H-1,2-benzazaphophole 2-oxide was synthesized analogously. Base-catalyzed N-alkylation of the benzazaphophole derivs. I (R = H) and IV was readily achieved, and the interconversion of 2-oxides and 2-sulfides was accomplished by conventional methods.


IT 90043-17-7P

RL SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 90043-17-7 CAPLUS



CN Phosphinic acid, phenyl[({2-[{2-(1-pyrrolidinylcarbonyl)benzoyl}amino]phenyl}methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	105.58	255.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-14.97	-14.97

STN INTERNATIONAL LOGOFF AT 12:40:41 ON 18 AUG 2003



chain nodes :

7 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 8 9 10 11 12

chain bonds :

6-14 7-8 7-13 14-15 15-16 15-19 16-17 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

7-8 7-13 8-9 8-12 9-10 10-11 11-12 15-16 15-19 16-17

exact bonds :

6-14 14-15 17-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:Atom 19:CLASS 24:CLASS